Description
Producer of pharmaceutical products intended to reduce manufacturing unit cost. The company's products are used to treat therapeutic diseases, enabling clinicians to provide treatment for pain management focusing on oncology-oriented diseases.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Secondary Transaction - Private | 01-Sep-2021 | 00000 | Completed | Generating Revenue | ||
4. Early Stage VC | 01-Sep-2012 | 0000 | 00000 | Completed | Generating Revenue | |
3. Grant | 20-Aug-2010 | 00000 | 00000 | Completed | Generating Revenue | |
2. Accelerator/Incubator | 12-Aug-2010 | $300K | $300K | Completed | Generating Revenue | |
1. Accelerator/Incubator | 07-Jan-2009 | Completed | Generating Revenue |
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20170296532-A1 | Compositions for control of drug abuse | Abandoned | 03-May-2012 | 0000000000 | |
US-20130295170-A1 | Compositions for control of drug abuse | Abandoned | 03-May-2012 | 0000000000 | 0 |
CA-2750219-A1 | Transdermal delivery of diclofenac, carbamazepine and benzydamine | Granted | 30-Jan-2009 | 00000000 | |
CA-2750219-C | Transdermal delivery of diclofenac, carbamazepine and benzydamine | Active | 30-Jan-2009 | 00000000 | |
US-20110294763-A1 | Transdermal delivery of dicolfenac, carbamazepine and benzydamine | Abandoned | 30-Jan-2009 | A61K31/55 | 0 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Stephen Dordunoo Ph.D | Founder, Chief Executive Officer, President & Chief Strategy Officer |